EDGAR 10-K Filing

Company CIK: 1098009
Filing Year: 2021
Filename: 1098009_10-K_2021_0001185185-21-000951.json

---

ITEM 1. BUSINESS
ITEM 1. BUSINESS
Historical Development
America Great Health, formerly Crown Marketing, is a Wyoming corporation (the "Company"). A change of control of the Company was completed on January 19, 2017 from Jay Hooper, the former officer and director of the Company and its former majority shareholder. Control was obtained by the sale of 16,155,746,000 shares of Company common stock from Mr. Hooper to an investor group led by Mike Q. Wang. In connection with the change of control, the Company sold to its former majority shareholder a subsidiary for $100 and another subsidiary in exchange for the cancellation of all payables and accrued expenses. After December 31, 2016, the Company’s operations are determined and structured by the new investor group. As such, the Company accounted for all of its assets, liabilities and results of operations up to January 1, 2017 as discontinued operations.
On March 1, 2017, the Company filed with the Secretary of State of the State of Wyoming an Articles of Amendment to change the corporate name from Crown Marketing to America Great Health.
On March 9, 2017, the Company formed a wholly owned subsidiary, America Great Health, under the laws of the State of California.
On June 24, 2019, the Company registered a wholly owned subsidiary in China, Meizhong Health Industry Development Co., Ltd. The subsidiary is mainly engaged in merger and acquisition, investment and financing, and marketing of medical equipment and health products in China.
Our Business
Prior to the change of controlling ownership of the common stock, the Company sold consumer products. It acquired electronic products from manufactures and then sold them directly to consumers so as to be more competitive in price. As of December 31, 2016, the Company ceased operations in this line of business.
The Company under the new management will focus its business in the health related industry. The Company’s Chairman and president, Mike Wang, is the owner of several health related businesses below with which The Company is evaluating the possibilities of forming several joint ventures. The Company might effectuate the joint ventures using stock.
1.
Health & Beauty Group Inc (“H&BG”). It is a California company in the business of research and development (“R&D”) and sale of vitamins and nutritional supplements. It owns more than 20 formulas and engages contract manufacturers to make these products. H&BG has built up sales records both in the US as well as in China. On January 4, 2018, the Company entered into a Stock Purchase Agreement with H&BG (the “Seller”) to purchase 51% of common shares of the Seller, for $765,000, which consisted of 63,750,000 outstanding shares of the Company’s common stock at $0.012 per share. On April 5, 2018, the Company entered into a Rescission Agreement (the “Rescission Agreement”) with the seller to rescind the transactions set forth in the Stock Purchase Agreement prior to the transaction closing.
2.
Pro Health Inc., a Tennessee company organized in 2016. It entered into a Sales Agreement with Provision Healthcare, LLC, a Tennessee limited liability company, in the selling of ProNova Equipment, which is a Proton Treatment device used in the treatment of cancer. Other than the sale of equipment, Pro Health will also provide Total Solution Services related with the use of the Equipment.
3.
Sales Agreement between Mike Wang and Dr. William Fang for the marketing and sales of Dr. Fang’s early detection system of Cardio Vascular diseases. The device provides unique 3D imaging for the Cardio Vascular conditions for patients and has already won approval of US Food and Drug Administration (“FDA”). It has very positive significance in helping preventing heart attacks, which are the number one killer in the US as well as in the world.
On March 5, 2018, America Great Health, a California Corporation (“AAGH CA”), a wholly owned subsidiary of the Company, entered into a Sino-foreign Co-operative Joint Venture Contract (the “JV Agreement”) with Guangzhou Bona Biotechnology Co., Ltd. (“Bona”) to establish a JV, Pomeikang Biotechnology (Guangzhou) Co., Ltd. (“Pomeikang”), to promote and develop sales channels for health and cosmetics related products supplied by AAGH CA in the mainland of the People’s Republic of China, the Hong Kong Special Administration Region and the Macau Special Administration Region (together, the “China Market”).
Pursuant to the JV Agreement, AAGH CA and Bona own 49% and 51% of Pomeikang, respectively, and AAGH California has the veto right to stop the majority shareholder’s decision. AAGH CA will contribute the initial products in equivalent of cash amount of RMB 2.45 million ($380,000) to Pomeikang and Bona will contribute any required operating capital, experienced sales team, promotional effort, and customer services to ensure normal day to day operation of Pomeikang. Bona will also be responsible for acquiring any required government permits, sales permits, and business licenses for Pomeikang.
At December 31, 2018, the Company decided to no longer participate in Pomeikang’s operations. On April 1, 2019, AAGH California transferred its 49% ownership to Bona for $1.
On May 21, 2018, the Company, entered into an Exclusive Oversea Distribution Agreement (the “Agreement”) with Foshan Wanshunbao Technology Co., Ltd. (“Wanshunbao”), a mainland China based company. According to the Agreement, Wanshunbao wishes to promote and develop oversea sales channels for its unique “Mysteries Fruit” tea and related products worldwide. The Company is appointed as Wanshunbao’s exclusive distributor to market and sell the “Mysteries Fruit” herbal tea and related products in geographic areas covers all over the world except mainland China.
In the past 20 years, Wangshunbao has dedicated to improve its R&D, and production of the unique “Mysteries Fruit” and related supplemental products, currently, Wangshunbao has developed a leading role in this industry, and is in the process of expanding its business model worldwide to a 10 billion RMB ($1,500,000,000) industry chain. To achieve that goal, Wangshunbao’s management team had been actively seeking a qualified international distributor and business partner to execute its expansion plan.
The Company’s management team was invited to Foshan, China in early May, 2018 to visit Wangshunbao and its production facilities, upon extensive discussion and negotiation, the Company was granted with exclusive distribution rights worldwide for “Mysteries Fruit” tea and related products. The Company believes by introducing “Mysteries Fruit” products to oversee consumers would have a huge beneficial effect; and the management is confident about this business opportunity, as the Company’s core team members all have been in health and supplemental related industry for over 20 years, and has substantial nutrient products sales experiences and marketing channels. The Company is currently conducting preliminary sales campaigns for “Mysteries Fruit” products.
The company and Blue Sea International Holdings Co., Ltd. signed a letter of intent on August 28, 2018. According to the letter of intent, Blue Sea International Holdings Co., Ltd. Intends to invest $50 million for the Company's marketing, product development, and merger and acquisition activities. The two parties also signed a marketing contract for 10,000 cardio vascular device after the Company obtains the necessary permit in China.
HuaHengJian (Beijing) Biotechnology Co., Ltd., Zhengzhou RuiBoSi Medical Devices Co., Ltd. and other companies have agreed to sell or lease more than 10,000 cardio vascular device in China after the Company obtains the necessary permit in China.
The company is negotiating an acquisition intention with Hongkong Pure Aesthetics Biotechnology Limited, which holds several patents in stem cell. The patents are valued at nearly $59 million.
The Company is discussing the possibility of establishing a joint venture in California with an individual who has nearly ten years experiences in health products market.
The Company is also planning to make additional acquisitions. Mike Wang has approached several health related companies in China and met the management of potential acquisition targets. Rapid economic advances in China in the last 30 years have greatly improved the living standards in China. This in turn brings demand in healthcare products and services. The Company feels strongly that despite the challenges of cross border business, it might be able to acquire some good growth companies and bring good values to our stockholders.
As inherent with any new business development, there are risks involved in such endeavors. For all the healthcare related businesses afore-mentioned, the Company is evaluating what kind of risks we are facing. The Company notices that vitamin and nutrition supplement business is a highly competitive market and faces multiple regulatory monitoring. The compliance challenge is constant. Regarding proton treatment sales, the device is very expensive and for such large ticket item, the procurement process can be long and arduous. The sale of cardio vascular device also has its challenges. The device is not well known and the acceptance of the use requires major efforts in educating not only the medical professionals but also consumers. This would demand financial as well as other resources. Although the Company is making some progress in the Merger and Acquisition efforts, any potential results, if any, are still not certain.
Employees and Outside Services
The company only has one executive and financial officer who devotes full time to the affairs of the Company. Remaining administrative (non-policy making) officers and consultants and technical personnel such as marketing specialists are being compensated as independent contractors. We pay these persons on a contract basis as required.

---

ITEM 1A. RISK FACTORS
ITEM 1A. RISK FACTORS
This item is inapplicable because we are a “smaller reporting company” as defined in Exchange Act Rule 12b-2.

---

ITEM 1B. UNRESOLVED STAFF COMMENTS
ITEM 1B. UNRESOLVED STAFF COMMENTS
This item is inapplicable because we are a “smaller reporting company” as defined in Exchange Act Rule 12b-2.

---

ITEM 2. PROPERTIES
ITEM 2. PROPERTIES
The Company currently is using a premise for free, the premise is leased by a company owned by its current majority shareholder.

---

ITEM 3. LEGAL PROCEEDINGS
ITEM 3. LEGAL PROCEEDINGS
No legal proceedings are threatened or pending against us or any of our officers or directors. Further, none of our officers, directors or affiliates are parties against us or have any material interests in actions that are adverse to the Company’s interests.

---

ITEM 4. MINE SAFETY DISCLOSURE
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
PART II

---

ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
Market Information
Our common stock is currently listed on the OTC Bulletin Board under the symbol “AAGH”. There has been limited trading of the common stock from December 2, 2013 (Inception) through June 30, 2020. The last sale price of our common stock on May 21, 2021 was $0.1679 per share.
The following table sets forth the high and low transaction price for each quarter within the fiscal years ended June 30, 2020 and 2019, as provided by the Nasdaq Stock Markets, Inc. The information reflects prices between dealers, and does not include retail markup, markdown, or commissions, and may not represent actual transactions.
Fiscal Year Ended
Bid Prices
June 30,
Period
High
Low
First Quarter
$ 0.0195
$ 0.0060
Second Quarter
$ 0.0180
$ 0.0051
Third Quarter
$ 0.0150
$ 0.0048
Fourth Quarter
$ 0.0120
$ 0.0050
First Quarter
$ 0.0150
$ 0.0090
Second Quarter
$ 0.0230
$ 0.0090
Third Quarter
$ 0.0230
$ 0.0098
Fourth Quarter
$ 0.0200
$ 0.0090
Our shares are subject to Section 15(g) and Rule 15g-9 of the Securities and Exchange Act, commonly referred to as the “penny stock” rule. The rule defines penny stock to be any equity security that has a market price less than $5.00 per share, subject to certain exceptions. The rule provides that any equity security is considered to be a penny stock unless that security is:
- registered and traded on a national securities exchange meeting specified criteria set by the SEC;
- issued by a registered investment company;
- excluded from the definition on the basis of price (at least $5.00 per share) or the issuer’s net tangible assets.
Trading in the penny stocks is subject to additional sales practice requirements on broker-dealers who sell penny stocks to persons other than established customers and accredited investors. Accredited investors, in general, include certain institutional investors and individuals with assets in excess of $1,000,000 or annual income exceeding $200,000 or $300,000 together with their spouse.
For transactions covered by these rules, broker-dealers must make a special suitability determination for the purchase of our securities and must have received the purchaser’s written consent to the transaction prior to the purchase. Additionally, for any transaction involving a penny stock, the rules require the delivery, prior to the first transaction, of a risk disclosure document relating to the penny stock. A broker-dealer also must disclose the commissions payable to both the broker-dealer and the registered representative, and current quotations for the security. Finally, monthly statements must be sent to the purchaser disclosing recent price information for the penny stocks. Consequently, these rules may restrict the ability of broker-dealers to trade or maintain a market in our common stock and may affect the ability of shareholders to sell their shares.
Holders
As of June 30, 2020, there were approximately 630 shareholders of record holding 20,236,021,836 shares of common stock. The holders of common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders. Holders of the common stock have no preemptive rights and no right to convert their common stock into any other securities. There are no redemption or sinking fund provisions applicable to the common stock.
Dividends
The Company has not paid any dividends on its common stock. The Company current intends to retain any earnings for use in its business, and therefore does not anticipate paying cash dividends in the foreseeable future.
Securities Authorized Under Equity Compensation Plans
The following table lists the securities authorized for issuance under any equity compensation plans approved by our shareholders and any equity compensation plans not approved by our shareholders as of June 30, 2020. This chart also includes individual compensation agreements.
EQUITY COMPENSATION PLAN INFORMATION
Plan category
Number of securities to
be issued upon exercise
of outstanding options,
warrants and rights
(a)
Weighted-average
exercise price of
outstanding options,
warrants and rights
(b)
Number of securities
remaining available for
future issuance under
equity compensation
plans (excluding
securities reflected in
column (a))
(c)
Equity compensation plans approved by security holders
$ 0.00
Equity compensation plans not approved by security holders
$ 0.00
Total
$ 0.00
Company repurchases of common stock during the year ended June 30, 2020
None
Performance Graphic
This item is not required to provide a performance graph since it is a “smaller reporting company” as defined in Exchange Act Regulation S-K Rule 10(f).
Share issuances in year ended June 30, 2020
All share issuances have been previously reported.

---

ITEM 6. SELECTED FINANCIAL DATA
ITEM 6. SELECTED FINANCIAL DATA
This item is inapplicable because we are a “smaller reporting company” as defined in Exchange Act Rule 12b-2.

---

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION
Forward Looking Statement Notice
This Current Report on Form 10-K contains forward-looking statements within the meaning of the federal securities laws. These include statements about our expectations, beliefs, intentions or strategies for the future, which we indicate by words or phrases such as “anticipate,” “expect,” “intend,” “plan,” “will,” “we believe,” “believes,” “management believes” and similar language. Except for the historical information contained herein, the matters discussed in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and elsewhere in this report are forward-looking statements that involve risks and uncertainties. The factors listed in the section captioned “Risk Factors,” as well as any cautionary language in this report; provide examples of risks, uncertainties and events that may cause our actual results to differ materially from those projected. Except as may be required by law, we undertake no obligation to update any forward-looking statement to reflect events after the date of this Form 10-K.
History and Organization
America Great Health, formerly Crown Marketing, is a Wyoming corporation (the “Company”). A change of control of the Company was completed on January 19, 2017 from Jay Hooper, the former officer and director of the Company and its former majority shareholder. Control was obtained by the sale of 16,155,746,000 shares of Company common stock from Mr. Hooper to an investor group led by Mike Q. Wang. In connection with the change of control, the Company sold to its former majority shareholder a subsidiary for $100 and another subsidiary in exchange for the cancellation of all payables and accrued expenses. After December 31, 2016, the Company’s operations are determined and structured by the new investor group. As such, the Company accounted for all of its assets, liabilities and results of operations up to January 1, 2017 as discontinued operations.
On March 1, 2017, the Company filed with the Secretary of State of the State of Wyoming an Articles of Amendment to change the corporate name from Crown Marketing to America Great Health.
On March 9, 2017, the Company formed a wholly owned subsidiary, America Great Health, under the laws of the State of California.
On June 14, 2019, the Company registered a wholly owned subsidiary in China, Meizhong Health Industry Development Co., Ltd. The subsidiary is mainly engaged in merger and acquisition, investment and financing, and marketing of medical equipment and health products in China.
Overview of Business
Prior to the change of controlling ownership of the common stock, the Company sold consumer products. It acquired electronic products from manufactures and then sold them directly to consumers so as to be more competitive in price. As of December 31, 2016, the Company ceased operations in this line of business.
The Company under the new management will focus its business in the health related industry. The Company’s Chairman and president, Mike Wang, is the owner of several health related businesses below with which The Company is evaluating the possibilities of forming several JVs. The Company might effectuate the JVs using stocks.
1.
H&BG. It is a California company in the business of R &D and sale of vitamins and nutritional supplements. It owns more than 20 formulas and engages contract manufacturers to make these products. The company has built up sales records both in the US as well as in China. On January 4, 2018, the Company entered into a Stock Purchase Agreement with H&BG (the “Seller”) to purchase 51% of common shares of the Seller, for $765,000, which consisted of 63,750,000 outstanding shares of the Company’s common stock at $0.012 per share. On April 5, 2018, the Company entered into a Rescission Agreement (the “Rescission Agreement”) with the seller to rescind the transactions set forth in the Stock Purchase Agreement prior to the transaction closing.
2.
Pro Health Inc., a Tennessee company organized in 2016. It entered into a Sales Agreement with Provision Healthcare , LLC, a Tennessee limited liability company, in the selling of ProNova Equipment, which is a Proton Treatment device used in the treatment of cancer. Other than the sale of equipment, Pro Health will also provide Total Solution Services related with the use of the Equipment.
3.
Sales Agreement between Mike Wang and Dr. William Fang for the marketing and sales of Dr. Fang’s early detection system of Cardio Vascular diseases. The device provides unique 3D imaging for the Cardio Vascular conditions for patients and has already won approval of US FDA. It has very positive significance in helping preventing heart attacks, which are the number one killer in the US as well as in the world.
On March 5, 2018, America Great Health, a California Corporation (“AAGH CA”), a wholly owned subsidiary of the Company, entered into a Sino-foreign Co-operative Joint Venture Contract (the “JV Agreement”) with Guangzhou Bona Biotechnology Co., Ltd. (“Bona”) to establish a JV, Pomeikang Biotechnology (Guangzhou) Co., Ltd. (“Pomeikang”), to promote and develop sales channels for health and cosmetics related products supplied by AAGH CA in the mainland of the People’s Republic of China, the Hong Kong Special Administration Region and the Macau Special Administration Region (together, the “China Market”).
Pursuant to the JV Agreement, AAGH CA and Bona each own 49% and 51% of Pomeikang, respectively, and AAGH California has the veto right to stop the majority shareholder’s decision. AAGH CA will contribute the initial products supply in equivalent of cash amount of RMB 2.45 million ($368,000) to Pomeikang and Bona will contribute any required operating capital, experienced sales team, promotional effort, and customer services to ensure normal day to day operation of Pomeikang. Bona will also be responsible for acquiring any required government permits, sales permits, and business licenses for Pomeikang.
At December 31, 2018, the Company decided to no longer participate in Pomeikang’s operations. On April 1, 2019, AAGH California transferred its 49% ownership to Bona for $1.
On May 21, 2018, the Company, entered into an Exclusive Oversea Distribution Agreement (the “Agreement”) with Foshan Wanshunbao Technology Co., Ltd. (“Wanshunbao”), a mainland China based company. According to the Agreement, Wanshunbao wishes to promote and develop overseas sales channels for its unique “Mysteries Fruit” tea and related products worldwide. The Company is appointed as Wanshunbao’s exclusive distributor to market and sell the “Mysteries Fruit” herbal tea and related products in geographic areas covers all over the world except mainland China.
In the past 20 years, Wangshunbao has dedicated to improve its R&D, and production of the unique “Mysteries Fruit” and related supplemental products, currently, Wangshunbao has developed a leading role in this industry, and is in the process of expanding its business model worldwide to a 10 billion RMB ($1.5 billion) industry chain. To achieve that goal, Wangshunbao’s management team had been actively seeking a qualified international distributor and business partner to execute its expansion plan.
The Company’s management team was invited to Foshan, China in early May, 2018 to visit Wangshunbao and its production facilities, upon extensive discussion and negotiation, the Company was granted with exclusive distribution rights worldwide for “Mysteries Fruit” tea and related products. The Company believes by introducing “Mysteries Fruit” products to oversee consumers would have a huge beneficial effect; and the management is confident about this business opportunity, as the Company’s core team members all have been in health and supplemental related industry for over 20 years, and has substantial nutrient products sales experiences and marketing channels. The Company is currently conducting preliminary sales campaigns for “Mysteries Fruit” products.
The company and Blue Sea International Holdings Co., Ltd. signed a letter of intent on August 28, 2018. According to the letter of intent, Blue Sea International Holdings Co., Ltd. Intends to invest $50 million for the Company's marketing, product development, and merger and acquisition activities. The two parties also signed a marketing contract for 10,000 cardio vascular device after the Company obtains the necessary permit in China.
HuaHengJian (Beijing) Biotechnology Co., Ltd., Zhengzhou RuiBoSi Medical Devices Co., Ltd. and other companies have agreed to sell or lease more than 10,000 cardio vascular device in China after the Company obtains the necessary permit in China.
The company is negotiating an acquisition intention with Hongkong Pure Aesthetics Biotechnology Limited, which holds several patents in stem cell. The patents are valued at nearly $59 million.
The Company is discussing the possibility of establishing a joint venture in California with an individual who has nearly ten years experiences in health products market.
The Company is also planning to conduct additional acquisitions. Mike Wang has approached several health related companies in China and met the management of potential acquisition targets. Rapid economic advances in China in the last 30 years have greatly improved the living standards in China. This in turn brings demand in healthcare products and services. The Company feels strongly that despite the challenges of cross border business, it might be able to acquire some good growth companies and bring good values to our stockholders.
As inherent with any new business development, there are risks involved in such endeavor. For all the healthcare related businesses afore-mentioned, the Company is evaluating what kind of risks we are facing. The Company notices that vitamin and nutrition supplement business is a highly competitive market and faces multiple regulatory monitoring. The compliance challenge is constant. Regarding proton treatment sales, the device is very expensive and for such large ticket item, the procurement process can be long and arduous. The sale of cardio vascular device also has its challenges. The device is not well known and the acceptance of the use requires major efforts in educating not only the medical professionals but also consumers. This would demand financial as well as other resources. Although the Company is making some progress in its Merger and Acquisition efforts, any results, are still not certain.
Critical Accounting Policies and Estimates
Estimates
The preparation of these consolidated financial statements (“CFS”) in accordance with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the consolidated financial statements and the reported amounts of net sales and expenses during the reported periods. Actual results may differ from those estimates and such differences may be material to the financial statements. The more significant estimates and assumptions by management include among others, the fair value of shares of common stock issued for services. The current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.
Recent Accounting Pronouncements
See Footnote 2 of the financial statements for a discussion of recently issued accounting standards.
Results of Operations
Results of Operations for the year ended June 30, 2020 compared to the year ended June 30, 2019.
There was no revenue and cost of sales for the year ended June 30, 2020.
Operating expenses for the year ended June 30, 2020 and 2019 was $48,256 and $46,771, respectively. The slight increase in the year ended June 30, 2020 was mainly due to the higher professional fee.
Our net loss for the year ended June 30, 2020 and 2019 was $51,916 and $65,043, respectively. The decrease in net loss in the year ended June 30, 2020 was mainly due to no loss on investment from the JV and no loss on disposal of JV investment, as wells as the gross profit generated by sales, partly offset by the higher operating expenses.
Liquidity and Capital Resources
Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate on an ongoing basis. Significant factors in the management of liquidity are funds generated by operations, levels of accounts receivable and accounts payable and capital expenditures.
The accompanying CFS were prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying CFS, the Company has incurred recurring net losses. For the year ended June 30, 2020, the Company recorded a net loss of $ $51,916, used cash to fund operating activities of $39,559, and at June 30, 2020, had a shareholders’ deficit of $215,007. For the year ended June 30, 2019, the Company recorded a net loss of $65,043, used cash to fund operating activities of $27,792. These factors create substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
The new management’s plans to continue as a going concern revolve around its ability to achieve profitable operations, as well as raise necessary capital to pay ongoing general and administrative expenses of the Company. The ability of the Company to continue as a going concern is dependent on securing additional sources of capital and the success of the Company’s plan. There is no assurance that the Company will be successful in raising the additional capital or in achieving profitable operations.
Our cash needs for the year ended June 30, 2020 were primarily met by loans and advances from current majority shareholder. As of June 30, 2020, we had cash balance of $166. Our new majority shareholders will need to provide all of our working capitals going forward.
Primarily as a result of our recurring losses and our lack of liquidity, we received a report from our independent registered public accounting firm for our financial statements for the year ended June 30, 2020 that includes an explanatory paragraph describing the uncertainty as to our ability to continue as a going concern.
Financial Position
As of June 30, 2020, we had $166 in cash, negative working capital of $215,007 and an accumulated deficit of $3,286,642.
Contractual Obligations and Off-Balance Sheet Arrangements
We do not have any contractual obligations or off balance sheet arrangements.

---

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

---

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
Our financial statements appear beginning on pagein this Form 10-K.

---

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
None

---

ITEM 9A. CONTROLS AND PROCEDURES
ITEM 9A. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Based upon an evaluation of the effectiveness of our disclosure controls and procedures performed by our Chief Executive Officer as of the end of the period covered by this report, our Chief Executive Officer concluded that our disclosure controls and procedures have not been effective as a result of a weakness in the design of internal control over financial reporting identified below.
As used herein, “disclosure controls and procedures” mean controls and other procedures of our company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Management’s Annual Report on Internal Control over Financial Reporting
Management is responsible for establishing and maintaining adequate internal control over financial reporting (“ICFR”), as such term is defined in Exchange Act Rule 13a-15(f) under the Securities Exchange Act of 1934. Our Chief Executive Officer/Chief Accounting Officer conducted an evaluation of the effectiveness of our ICFR based on the framework in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO 2013”). Based on management’s evaluation under the framework, management has concluded that our ICFR was not effective as of June 30, 2020.
We identified material weaknesses in our ICFR primarily attributable to (i) lack of segregation of incompatible duties; and (ii) insufficient Board of Directors representation. These weaknesses are due to our inadequate staffing during the period covered by this report and our lack of working capital to hire additional staff. Management has retained an outside, independent financial consultant to record and review all financial data, as well as prepare our financial reports, in order to mitigate this weakness. Although management will periodically re-evaluate this situation, at this point it considers that the risk associated with such lack of segregation of duties and the potential benefits of adding employees to segregate such duties are not cost justified. We intend to hire additional accounting personnel to assist with financial reporting as soon as our finances will allow.
This annual report does not include an attestation report of our registered public accounting firm regarding ICFR. Management’s report was not subject to attestation by our registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit us to provide only management’s report in this annual report.

---

ITEM 9B. OTHER INFORMATION
ITEM 9B. OTHER INFORMATION
None.
PART III

---

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
Directors and Executive Officers
The members of the Board of Directors (“BOD”) of the Company serve until the next annual meeting of stockholders, or until their successors have been elected. The officers serve at the pleasure of the BOD. The following are the directors, executive officers and key employees of the Company.
Our management team is headed by experienced Chief Executive Officer Mike Wang, who was elected on March 1, 2017.
Mike Wang, age 67, has been working in the health supplements business for about 20 years. He is the President of America Great Health. And he is also the vice-president of the American Nutrition and Health Association in Los Angeles, California.
Code of Ethics
The Company has not adopted a code of ethics which applies to the chief executive officer, or principal financial and accounting officer, because of our current low level of operations as a public entity. The Company intends to adopt a code of ethics in near future.
Audit Committee Financial Expert
The Company does not have either an Audit Committee or a financial expert on the BOD. The BOD believes that obtaining the services of an audit committee financial expert is not economically rational at this time in light of the costs associated with identifying and retaining an individual who would qualify as an audit committee financial expert, the limited scope of our operations and the relative simplicity of our financial statements and accounting procedures.
Section 16(a) Beneficial Ownership Reporting Compliance
Section 16(a) of the Exchange Act requires the Company's officers, directors and persons who own more than 10 percent of a registered class of our equity securities to file reports of ownership and changes in ownership with the SEC. Officers, directors and ten percent stockholders are required by regulation to furnish the Company with copies of all Section 16(a) forms they file. During the year ended June 30, 2020, the Company believes that all such persons failed to file the reports required by Section 16(a) of the Exchange Act, including Forms 3, 4 and 5. Based on representations submitted by such people, the Company does not believe that such individuals purchased or sold any Common Stock of the Company through public exchange during the year ended June 30, 2020.

---

ITEM 11. EXECUTIVE COMPENSATION
ITEM 11. EXECUTIVE COMPENSATION
Executive Officers and Directors
The following tables set forth certain information about compensation paid, earned or accrued for services by (i) the Company’s Chief Executive Officer in the years ended June 30, 2020 and 2019 (“Named Executive Officers”):
Name and
Principal
Position
Year
Salary
($)
Bonus
($)
Stock
Awards
($)
Option
Awards
($)
Non-Equity
Incentive
Plan
Compensation
($)
Nonqualified
Deferred
Compensation
($)
All Other
Compensation
($)
Total
($)
Mike Wang
Chief Executive/Chief Financial Officer
-
-
-
-
-
-
-
-
Mike Wang
Chief Executive/Chief Financial Officer
-
-
-
-
-
-
-
-
Employment Contracts
We currently do not have any written employment agreements with our executive officers.
Director Compensation
Our directors currently serve without compensation.

---

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
Beneficial Ownership
The following table sets forth, as of the date of this Report the outstanding common stock of the Company owned of record or beneficially by each person who owned of record, or was known by the Company to own beneficially, more than 5% of the Company’s 20,236,021,836 shares of common stock issued and outstanding, and the name and shareholdings of each director and all of the executive officers and directors as a group:
CERTAIN BENEFICIAL OWNERS
Name
Office
Amount and
nature of
beneficial owner (1)
Percent
of class
Mike Wang (2)
CEO, CFO, Director
8,565,142,133
42.33
%
All officer and directors as a group (1 person)
N/A
8,565,142,133
42.33
%
(1)
Except as otherwise noted, shares are owned beneficially and of record, and such record shareholder has sole voting, investment and dispositive power.

---

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
During the year ended June 30, 2020, the Company's current majority shareholder advanced $121,840 to the Company as working capital and the Company repaid $82,217 to the shareholder. As of June 30, 2020 and 2019, the Company owed its current majority shareholder of $168,028 and $128,404 respectively. The advances are non-interest bearing and are due on demand.
The Company currently is using a premise for free, the premises is leased by a company owned by its current majority shareholder.
Director Independence
Currently, the Company does not have any independent directors. Since the Company’s Common Stock is not currently listed on a national securities exchange, we have used the definition of “independence” of The NASDAQ Stock Market to make this determination.
Under NASDAQ Listing Rule 5605(a)(2), an "independent director" is a "person other than an officer or employee of the company or any other individual having a relationship which, in the opinion of the company's board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director."
We do not currently have a separately designated audit, nominating or compensation committee. However, we do intend to comply with the independent director and committee composition requirements in the future.

---

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES
ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES
The following table sets forth the fees paid by the Company for professional services rendered for the audits of the annual financial statements and fees billed for other services rendered by its principal accountants:
Type of Services Rendered
Audit Fees
$ 20,000
$ 20,000
Audit-Related Fees
$ -
$ -
Tax Fees
$ -
$ -
All Other Fees
$ -
$ -
Pre-approval Policies
We do not have a standing audit committee currently serving and as a result our BOD performs the duties of an audit committee. Our BOD evaluates and approves, in advance, the scope and cost of the engagement of an accounting firm before the accounting firm renders audit and non-audit services. We do not rely on pre-approval policies and procedures.
PART IV

---

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
1.
(a) Financial Statements.
Report of Independent Registered Public Accounting Firm
Consolidated Balance Sheets as of June 30, 2020 and 2019
Consolidated Statements of Operations for the Years Ended June 30, 2020 and 2019
Consolidated Statements of Shareholders’ Deficit for the Years Ended June 30, 2020 and 2019
Consolidated Statements of Cash Flows for the Years Ended June 30, 2020 and 2019
Notes to Consolidated Financial Statements
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Stockholders
America Great Health and Subsidiaries
Opinion on the Consolidated Financial Statements
We have audited the accompanying consolidated balance sheets of America Great Health and Subsidiaries (the “Company”) as of June 30, 2020 and 2019, and the related statements of operations, stockholders' deficit, and cash flows for the year then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2020, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States.
Going Concern Matter
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses from operations that raises substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Basis for Opinion
These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. Our audits included performing procedures to assess the risks of material misstatement, whether due to error fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.
/s/ TAAD, LLP
We have served as the Company’s auditor since 2020, and we previously served as the Company’s auditor from 2016 through 2018
Diamond Bar, California
July 12, 2021
America Great Health and Subsidiaries (fka “ Crown Marketing”)
Consolidated Balance Sheets
June 30,
June 30,
ASSETS
CURRENT ASSETS
Cash
$
$
Inventory
1,141
-
Other receivable
2,587
-
TOTAL CURRENT ASSETS
3,894
TOTAL ASSETS
$ 3,894
$
LIABILITIES AND SHAREHOLDERS' DEFICIT
CURRENT LIABILITIES
Accounts payable and accrued expense
$ 49,273
$ 38,900
Income tax payable
1,600
Due to related party
168,028
128,404
TOTAL CURRENT LIABILITIES
218,901
168,104
SHAREHOLDERS' DEFICIT
Redeemable, convertible preferred stock, 10,000,000 shares authorized;
Series A voting preferred stock, zero shares issued and outstanding
-
-
Common stock, no par value, unlimited shares authorized;
20,236,021,836 and 20,236,021,836 shares issued and outstanding
-
-
Additional paid-in capital
3,071,635
3,066,724
Accumulated deficit
(3,286,642 )
(3,234,726 )
TOTAL SHAREHOLDERS' DEFICIT
(215,007 )
(168,002 )
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT
$ 3,894
$
The accompanying notes are an integral part of these consolidated financial statements.
America Great Health and Subsidiaries (fka “ Crown Marketing”)
Consolidated Statements of Operations
Year Ended June 30,
Sales
$ 5,474
$ -
Cost of goods sold
3,369
-
Gross profit
2,105
-
Selling, general and administrative expenses
Professional fee
34,255
33,507
Other
14,001
13,264
48,256
46,771
Loss from operations
(46,151 )
(46,771 )
Other income (expenses)
Interest expense
(4,965 )
(4,494 )
Loss on investment
-
(966 )
Loss on disposal of investment
-
(12,012 )
(4,965 )
(17,472 )
Loss before income tax
(51,116 )
(64,243 )
Income tax provision
NET LOSS
$ (51,916 )
$ (65,043 )
BASIC AND DILUTED LOSS PER SHARE
$ (0.00 )
$ (0.00 )
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING
BASIC AND DILUTED
20,236,021,836
20,236,021,836
The accompanying notes are an integral part of these consolidated financial statements.
America Great Health and Subsidiaries (fka “Crown Marketing”)
Consolidated Statement of Shareholders' Deficit
Preferred Stock
Common Stock
Additional
Accumulated
Shares
Amount
Shares
Amount
Paid-in Capital
Deficit
Total
Balance, June 30, 2018
-
$ -
20,236,021,836
$ -
$ 3,062,230
$ (3,169,683
)
$ (107,453
)
Imputed Interest
-
-
-
-
4,494
-
4,494
Net loss
-
-
-
-
-
(65,043
)
(65,043
)
Balance, June 30, 2019
-
-
20,236,021,836
-
3,066,724
(3,234,726
)
(168,002
)
Imputed Interest
-
-
-
-
4,911
-
4,911
Net loss
-
-
-
-
-
(51,916
)
(51,916
)
Balance, June 30, 2020
-
$ -
20,236,021,836
$ -
$ 3,071,635
$ (3,286,642
)
$ (215,007
)
The accompanying notes are an integral part of these consolidated financial statements.
America Great Health and Subsidiaries (fka “ Crown Marketing”)
Consolidated Statements of Cash Flows
Year Ended June 30
Cash Flows from Operating Activities
Net loss
$ (51,916 )
$ (65,043 )
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on investment
-
Loss on disposal of investment
-
12,012
Imputed interest
4,911
4,494
Changes in operating Assets and Liabilities:
Inventory
(1,141 )
-
Other receivable
(2,587 )
Accounts payable and accrued expense
10,374
18,879
Income tax payable
Net cash used in operating activities
(39,559 )
(27,792 )
Cash Flows from Financing Activities
Advances from related party
121,840
29,379
Repayment to related party
(82,217 )
(1,500 )
Net cash provided by financing activities
39,623
27,879
Net increase (decrease) in cash
Cash beginning of period
Cash end of period
$
$
Interest paid
$ -
$ -
Taxes paid
$ -
$ -
The accompanying notes are an integral part of these consolidated financial statements.
AMERICA GREAT HEALTH AND SUBSIDIARIES
(FORMERLY KNOWN AS CROWN MARKETING)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2020 AND 2019
NOTE 1 - NATURE OF BUSINESS
History and Organization
America Great Health, formerly Crown Marketing, is a Wyoming corporation (the "Company"). A change of control of the Company was completed on January 19, 2017 from Jay Hooper, the former officer and director of the Company and its former majority shareholder. Control was obtained by the sale of 16,155,746,000 shares of Company common stock from Mr. Hooper to an investor group led by Mike Q. Wang. In connection with the change of control, the Company sold to its former majority shareholder a subsidiary for $100 and another subsidiary in exchange for the cancellation of all payables and accrued expenses. After December 31, 2016, the Company’s operations are determined and structured by the new investor group. As such, the Company accounted for all of its assets, liabilities and results of operations up to January 1, 2017 as discontinued operations.
On March 1, 2017, the Company filed with the Secretary of State of the State of Wyoming an Articles of Amendment to change the corporate name from Crown Marketing to America Great Health.
On March 9, 2017, the Company formed a wholly owned subsidiary, America Great Health, under the laws of the State of California.
On June 24, 2019, the Company registered a wholly owned subsidiary in China, Meizhong Health Industry Development Co., Ltd. The subsidiary is mainly engaged in merger and acquisition, investment and financing, and marketing of medical equipment and health products in China.
Going Concern
The accompanying consolidated financial statements (“CFS”) were prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying CFS, the Company has incurred recurring net losses. For the year ended June 30, 2020, the Company recorded a net loss of $51,916, used cash to fund operating activities of $39,559, and at June 30, 2020, had a shareholders’ deficit of $215,007. These factors create substantial doubt about the Company's ability to continue as a going concern. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
During the year ended June 30, 2017, the Company’s former majority shareholder sold his shares to an investor group. The new owners’ plans to continue as a going concern revolve around its ability to achieve profitable operations, as well as raise necessary capital to pay ongoing general and administrative expenses of the Company. The ability of the Company to continue as a going concern is dependent on securing additional sources of capital and the success of the Company’s plan. There is no assurance that the Company will be successful in raising the additional capital or in achieving profitable operations.
Our cash needs for the 12 months ended June 30, 2020 were primarily met by loans and advances from current majority shareholder. As of June 30, 2020, we had a cash balance of $166. We intend to finance operating costs over the next twelve months with existing cash on hand and advance from current majority shareholder.
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The accompanying CFS were prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”).
Basis of Consolidation
The CFS includes the accounts of the Company and its current wholly owned subsidiaries, America Great Health in California and Meizhong Health Industry Development Co., Ltd, Intercompany transactions and accounts were eliminated in consolidation.
Estimates
The preparation of the financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include accounting for potential liabilities and the assumptions made in valuing stock instruments issued for services. Actual results could differ from those estimates.
Revenues
Revenue from sale of goods under Topic 606, Revenue from Contracts with Customers, is recognized in a manner that reasonably reflects the delivery of the Company’s products and services to customers in return for expected consideration and includes the following elements:
●
executed contract(s) with customers that the Company believes is legally enforceable;
●
identification of performance obligation in the respective contract;
●
determination of the transaction price for each performance obligation in the respective contract;
●
allocation of the transaction price to each performance obligation; and
●
recognition of revenue only when the Company satisfies each performance obligation.
Inventories
Inventories are stated at the lower of cost (first-in, first-out) or net realizable value. Adjustments to reduce the cost of inventory to its net realizable value are made, if required, for estimated excess, obsolescence, or impaired balances.
Fair Value Measurements
Fair value measurements are determined using authoritative guidance issued by the FASB, with the exception of the application of the guidance to non-recurring, non-financial assets and liabilities as permitted. Fair value is defined in the authoritative guidance as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels as follows:
Level 1-Quoted prices in active markets for identical assets or liabilities.
Level 2-Inputs, other than the quoted prices in active markets, are observable either directly or indirectly.
Level 3-Unobservable inputs based on the Company’s assumptions.
The Company is required to use observable market data if available without undue cost and effort.
The Company’s financial instruments include cash and accounts payable. Management has estimated that the carrying amounts approximate their fair value due to the short-term nature.
Loss per Share
Basic earnings (loss) per share are computed by dividing income available to common shareholders by the weighted-average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company’s diluted loss per share is the same as the basic loss per share for the years ended June 30, 2020 and 2019, as there are no potential shares outstanding that would have a dilutive effect.
Income Taxes
Income tax expense is based on pretax financial accounting income. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized. The Company recorded a valuation allowance against its deferred tax assets as of June 30, 2020 and 2019.
The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. The Company classifies the liability for unrecognized tax benefits as current to the extent that the Company anticipates payment (or receipt) of cash within one year. Interest and penalties related to uncertain tax positions are recognized in the provision for income taxes.
Recent Accounting Pronouncements
In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, as part of its initiative to reduce complexity in accounting standards. The amendments in the ASU are effective for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company is currently evaluating the effect, if any, that the ASU will have on its consolidated financial statements.
Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or is not believed by management to have a material impact on the Company’s present or future consolidated financial statements.
NOTE 3 - RELATED PARTY TRANSACTIONS
During the year ended June 30, 2020, the Company's current majority shareholder advanced $121,840 to the Company as working capital and the Company repaid $82,217 to the shareholder. As of June 30, 2020 and 2019, the Company owed its current majority shareholder of $168,028 and $128,404 respectively. The advances are non-interest bearing and are due on demand.
Currently the Company is using a premise for free, the premises is leased by a company owned by its current majority shareholder.
NOTE 4 - SHAREHOLDERS’ DEFICIT
At June 30, 2020 and 2019, the Company had 20,236,021,836 shares issued and outstanding.
NOTE 5 - JOINT VENTURE
On March 5th, 2018, America Great Health, a California Corporation (“AAGH California”), a wholly owned subsidiary of the Company, entered into a Sino-foreign Co-operative Joint Venture Contract (the “JV Agreement”) with Guangzhou Bona Biotechnology Co., Ltd. (“Bona”) pursuant to which the parties established a JV, Pomeikang Biotechnology (Guangzhou) Co., Ltd. (“Pomeikang”) to promote and develop sales channels for health and cosmetics related products supplied by AAGH California in the mainland of the People’s Republic of China, the Hong Kong Special Administration Region and the Macau Special Administration Region (together, the “China Market”).
Pursuant to the JV Agreement, AAGH California and Bona will each own 49% and 51% of the JV Company, respectively, and AAGH California has the veto right to the majority shareholder’s decision. The equity method has been used for this JV. AAGH California will contribute the initial products supply in equivalent of cash amount of RMB 2.45 million to the JV Company and Bona will contribute any required operating capitals, experienced sales team, promotional effort, and customer services to ensure normal day to day operation of the JV Company. Bona will also be responsible for acquiring any required government permits, sales permits, and business licenses for the JV Company.
The following table summarizes the income statement of Pomeikang.
From date of equity
investment to 12/31/2018
Sales
$ 20,740
Gross profit
13,739
Net loss
(2,803
)
49% share
(1,373
)
The following table provides the summary of balance sheet information for Pomeikang.
As of December 31, 2018
Total assets
$ 20,565
Net assets
20,565
49% ownership
10,077
Ending balance of investment account before written off
12,012
Difference
(1,932
)
The difference of $1,932 was mainly due to the effect of exchange rate.
There was no operation during the period from October 1, 2018 to December 31, 2018, therefore at December 31, 2018, the Company decided to no longer participate in Pomeikang’s operations. As a result, a loss on disposal of investment of $12,012 was recorded at December 31, 2018. On April 1, 2019, AAGH California transferred its 49% ownership to Bona for $1.
NOTE 6 - INCOME TAXES
Deferred taxes represent the net tax effects of the temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes. Temporary differences result primarily from the recording of tax benefits of net operating loss carry forwards.
As of June 30, 2020, the Company has an insufficient history to support the likelihood of ultimate realization of the benefit associated with the deferred tax asset. Accordingly, a valuation allowance has been established for the full amount of the net deferred tax asset.
The Company’s effective income tax rate differs from the amount computed by applying the federal statutory income tax rate to loss before income taxes for the years ended June 30, 2020 and 2019 as follows:
Year Ended June 30,
Income tax benefit at federal statutory rate
%
%
State tax, net of fed effect
%
%
Change in valuation allowance
%
%
-
%
-
%
The components of deferred taxes consist of the following at June 30, 2020 and 2019:
June 30, 2020
June 30, 2019
Net operating loss carryforwards
$ 238,591
$ 905,723
Less: valuation allowance
(238,591
)
(905,723
)
Net deferred tax assets
$ -
$ -
As of June 30, 2020, the Company had federal and California income tax net operating loss carryforwards of $852,111 . These net operating losses originating in tax years beginning prior to Jan. 1, 2018 will begin to expire 20 years from the date the tax returns are filed. The net operating losses originating in tax years beginning after Jan. 1, 2018 will be carry forwarded indefinitely.
NOTE 8 - SUBSEQUENT EVENTS
On December 7, 2020, America Great Health, a California Corporation (“AAGH California”), a wholly owned subsidiary of the Company, entered into a Cooperation Agreement (the “Agreement”) with Brilliant Healthcare Limited. (“Brilliant”) pursuant to which the parties will establish a joint venture in China (the “JV Company”) for the purpose of promoting and developing stem cell related product’s R&D, production, sales, row material procumbent, mergers and acquisitions, and consulting services. As of the time of filing these financial statements with the Company’s annual report, the formation of the JV Company has not been completed. After the formation of the JV company is completed, the Company shall invest USD $4.2 million in the JV Company within the next 24 months for 60% equity ownership of the JV Company, Brilliant shall transfer its patented technology (with estimated value of USD $29.8 million) to the JV Company as its capital contribution, to account for 40% equity ownership.
1) Shares issued for merger & acquisition
Investment in Brilliant Healthcare Limited
On December 7, 2020, America Great Health, a California Corporation (“AAGH California”), a wholly owned subsidiary of the Company, entered into a Cooperation Agreement (the “Agreement”) with Brilliant Healthcare Limited. (“Brilliant”) pursuant to which the parties will establish a joint venture in China (the “JV Company”) for the purpose of promoting and developing stem cell related product’s R&D, production, sales, row material procumbent, mergers and acquisitions, and consulting services. As of the time of filing these financial statements with the Company’s annual report, the formation of the JV Company has not been completed. After the formation of the JV company is completed, the Company shall invest USD $4.2 million in the JV Company within the next 24 months for 60% equity ownership of the JV Company, Brilliant shall transfer its patented technology (with estimated value of USD $29.8 million) to the JV Company as its capital contribution, to account for 40% equity ownership.
Investment in Imedipus Inc.
On January 30, 2020, the Company and Imediplus Inc. (“Imediplus”), a leading medical institution in Taiwan, entered into a Cooperation Agreement, in which the Company agreed to acquire 48% of the equity of Imediplus, as consideration, the Company shall pay $1,000,000 and issue 662,000,000 common shares to Imediplus. Upon completion of the acquisition transaction, Purecell shall remain autonomy in its day to day operation, including recruiting and retaining management team members.
As of June 30, 2021, the Company has not completed its financial and legal due diligence and has not consummated the acquisition of Imediplus.
On April 6, 2021, the Company issued 70,000,000 shares to a director of Imediplus as collateral in exchange for getting trust of 2,500,000 shares that is 5% of Imediplus.
Investment in Purecell Group
On June 30, 2020, the Company and Purecell Group (“Purecell”), a leading anti-aging medical institution in Australia, entered into a Cooperation Agreement, in which the Company agreed to acquire 51% of the equity of Purecell, as consideration, the Company shall issue 510,000,000 common shares to Purecell’s nominated trustee. Upon completion of the acquisition transaction, Purecell shall remain autonomy in its day to day operation, including recruiting and retaining management team members. On February 10, 2021, the Company completed its financial and legal due diligence. On April 6, 2021, the Company issued 510,000,000 shares to two shareholders of Purecell Group PTY Ltd ("Purecell") in exchange of 51% of ownership of Purecell. On April 6, 2021, the Company issued 50,000,000 shares of common stock to Purecell’s project introducer as compensation for services, at market price of $0.14 per share.
On May 11, 2021, Aussie Produce PTY LTD ("AP") signed agreement with Purecell to invest $2,340,000 in exchange of 6% of total outstanding shares of Purecell and 35,000,000 shares of the Company owned by Purecell. Purecell will issue 6% shares to AP in exchange for the $2,340,000 investment. In addition, Purecell will issue 68,372 shares to AP and issue 71,163 shares to the Company. The Company will also issue additional 31,212,000 shares to Purecell. Purecell will use the proceeds to acquire VERITA PHARMA, which is a medicine factory. On May 26, 2021, the Company issued 35,000,000 shares to shareholder of AP.
2) Shares issued for stock compensation
On January 22, 2021, the Company issued an aggregate of 48,220,124 shares of common stock to 28 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.06 per share.
On March 10, 2021, the Company issued an aggregate of 79,362,534 shares of common stock to 54 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.13 per share.
On April 7, 2021, the Company issued an aggregate of 6,621,905 shares of common stock to 12 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.13 per share.
On May 5, 2021, the Company issued an aggregate of 1,300,000 shares of common stock to 6 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.14 per share.
On May 18, 2021, the Company issued an aggregate of 7,140,000 shares of common stock to 5 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.14 per share.
On May 18, 2021, the Company and David Tsai (“Dr. Tsai”), a pioneer in anti-cancer peptide research and invention in the United States, entered into a Cooperation Agreement, in which Dr. Tsai shall provide to the Company of relevant theories, technologies, methods, sources of raw materials, processing and production techniques, quality standards, quality control methods and other information and details related to his anti-cancer protein peptides, oral insulin and activation technology; Dr. Tsai shall also be responsible for the whole process of technology and product production, application and implementation, as well as professional technical support, consultation and cooperation in the process of product verification, publicity, promotion and sales. As consideration, the Company agreed to grant 8 million shares of AAGH common stock to Dr. Tsai along with certain monthly compensations and sales bonus.
On May 26, 2021, the Company issued an aggregate of 2,450,000 shares of common stock to 6 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.15 per share.
On June 18, 2021, the Company issued an aggregate of 11,300,000 shares of common stock to 22 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.16 per share.
3) Shares issued for loan as collateral
On May 5, 2021, the Company issued 10,000,000 shares to an unrelated party as collateral for a loan of $200,000. The loan has an annual interest rate of 20%. The principle and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principle and interest are paid in full. If the Company's stock price remains above $0.04 continuously over 30 days following the maturity date, the stock will become tradable and the remaining principle and interest of loan will be forgiven. The Company received the proceed on April 27, 2021.
On June 18, 2021, the Company issued an aggregate of 3,050,000 shares to 6 unrelated parties as collateral for loans of $290,000. The loans have an annual interest rate of 20%. The principle and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principle and interest are paid in full. If the Company's stock price remains above $0.2 continuously over 30 days following the maturity date, the stock will become tradable and the remaining principle and interest of loan will be forgiven. The Company received the proceed on June 3, 2021.
On June 18, 2021, the Company issued 500,000 shares to an unrelated party as collateral for a loan of $50,000. The loan has an annual interest rate of 20%. The principle and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principle and interest are paid in full. If the Company's stock price remains above $0.2 continuously over 30 days following the maturity date , the stock will become tradable and the remaining principle and interest of loan will be forgiven. The Company received the proceed on June 4, 2021.
(b) Exhibits. The following exhibits of the Company are included herein.
2. Agreement and Plan of Reorganization
2.1 Agreement and Plan of Reorganization between the Company and Okra Energy, Inc. dated December 2, 2013.(4)
3. Certificate of Incorporation and Bylaws
3.1. Articles of Incorporation (1)*
3.2 Articles of Merger (2)
3.3 Bylaws(1)
3.4 Amended and Restated Articles of Incorporation, as filed June 24, 2016(5)
3.5 Amendment to Articles of Incorporation increasing authorized Series A Preferred, August 20, 2016(5)
10. Material Contracts
10.1 Promissory Note to Strategic Global Resources, Ltd. (3)
10.2 Promissory Note to Farrington Pharmaceuticals, LLC (3)
10.3 Lease Agreement between Okra Energy, Inc. and Temple CB, LLC (4)
21. Subsidiaries of the registrant - Okra Energy, a California corporation and Crown Laboratory, Inc. Crown Mobile is a California corporation which is 50% owned by the Company. No trade names are employed.
31.1 Certification by the Principal Executive Officer and Principal Accounting and Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1. Certifications by the Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
* The Company had filed an amendment to its Articles of Incorporation to change the name to “Okra, Inc.’ but this amendment was reversed in an additional amendment filed with the Secretary of State. The name of the Company continues to be “Crown Marketing.”
All other Exhibits called for by Rule 601 of Regulation S-K are not applicable to this filing.
(1) Filed with original registration statement.
(2) Filed with amendment no. 1.
(3) Filed with the Annual Report on Form 10-K for the year ended June 30, 2013.
(4) Filed with Current Report on Form 8-K dated December 2, 2013.
(5) Filed with the Annual Report on Form 10-K for the year ended June 30, 2016.